LB Pharmaceuticals has appointed Joseph Miller as Chief Financial Officer, adding a biopharmaceutical finance executive with more than two decades of experience spanning financial strategy, operations and organizational transformation.
The appointment comes as LB Pharmaceuticals approaches a potentially important development period involving its lead drug candidate LB-102 and the upcoming NOVA-2 clinical trial readout.
Miller most recently served as Chief Financial Officer of Aurinia Pharmaceuticals, where he helped build and scale the company’s financial and operational infrastructure during its transition from late-stage clinical development into commercialization.
During his tenure, Aurinia launched LUPKYNIS, or voclosporin, the first FDA-approved oral therapy for active lupus nephritis.
Miller also oversaw revenue growth, profitability and an ex-U.S. licensing and collaboration agreement with Otsuka Pharmaceutical.
Previously, Miller served as Chief Financial Officer, Principal Executive Officer and Corporate Secretary of Avalo Therapeutics, formerly Cerecor.
At Avalo, he led the acquisitions of Aevi Genomic Medicine and Ichorion Therapeutics and helped execute the divestiture of the company’s commercial portfolio to Aytu BioScience.
Earlier, Miller served as Vice President of Finance at Sucampo Pharmaceuticals, where he helped build the finance organization during a period of rapid expansion that ultimately culminated in Sucampo’s merger with Mallinckrodt.
He has also held finance roles at QIAGEN, Eppendorf and KPMG.
Miller holds a B.S. in accounting from Villanova University and is a Certified Public Accountant.
LB Pharmaceuticals is developing neuromedicines for underserved brain disorders.
Its lead candidate, LB-102, is being developed as a potential benzamide antipsychotic treatment for neuropsychiatric disorders, including schizophrenia.
KEY QUOTES:
“We are pleased to welcome Joe to the team as we enter a potentially transformative period for the company. As we approach our pivotal NOVA-2 clinical trial results and continue preparing for the potential launch of LB-102 in schizophrenia, Joe’s extensive experience guiding companies from pivotal data through commercialization will be a tremendous asset. His success in building high-performing financial and operational organizations will help position us to drive long-term value creation.”
Heather Turner, Chief Executive Officer of LB Pharmaceuticals
“LB Pharmaceuticals has built exceptional momentum as we approach the NOVA-2 readout, a key milestone for our next chapter of growth. I am thrilled to join the company and work with the team to strengthen our organizational readiness for the exciting road ahead as we prepare for the potential commercialization of LB-102.”
Joseph Miller, Chief Financial Officer of LB Pharmaceuticals
